Immunodeficiency-associated lymphoproliferative disorders (LPD) represent a rare life-threatening clinical entity characterized by heterogeneous histological findings that range from polymorphic to monomorphic proliferated abnormal lymphocytes. Currently, there is no standard treatment for LPD. To elucidate the clinical features and treatment outcomes of immunodeficiency-associated LPD patients with rheumatoid arthritis (RA), we retrospectively evaluated 9 cases observed over a 5-year period. The diagnoses of these patients included 5 diffuse large B-cell lymphomas, 3 LPD, and 1 mucosa-associated lymphoid tissue lymphoma. At initial diagnosis, 6 patients had advanced-stage RA, and half of these underwent total knee arthroplasty. All patients with RA received methotrexate (MTX) and low-dose prednisolone. Biologics were administered to 4 of 9 patients. After the development of immunodeficiency-associated LPD, MTX discontinuation resulted in 5 complete remissions (CR), 1 partial remission, and 3 cases of stable disease. Relapse was observed in 3 of 5 CR patients in the MTX-withdrawal remission group. Subsequently, conventional chemotherapy, rituximab, and radiation were administered to 4, 3, and 1 patient, respectively. These treatments induced a second CR. In the chemotherapy group, 1 patient developed acute myocardial infarction and another experienced ileus and pulmonary abscess. In the rituximab group, no severe complications were observed. Consequently, all patients remained disease-free during the median 23-month follow-up period. Our results indicate that, depending on the RA disease stage, performance status, and extent of treatment response, less intensive treatments than those commonly indicated for non-Hodgkin lymphoma, involving MTX discontinuation and subsequent therapy containing rituximab, might be an efficient therapeutic strategy for immunodeficiency-associated LPD.
INTRODUCTION
Rheumatoid arthritis (RA) is a progressive, chronic autoimmune inflammatory disease that is currently treated with various immunosuppressive agents, such as prednisolone (PSL), methotrexate (MTX), rituximab, anti-tumor necrosis factor-a inhibitors, and anti-interleukin-6 receptor inhibitors. [1] [2] [3] [4] Of these, MTX is considered the mainstream treatment of RA. 5, 6 The incidence of malignant lymphoma (ML) has been reported to be higher in patients with RA than in the general population. [7] [8] [9] Moreover, immunosuppressive agents such as MTX have been reported to increase the risk of ML development. [7] [8] [9] Immunodeficiency-associated lymphoproliferative disorder (LPD) is a rare and lethal clinical entity characterized by heterogeneous histological findings that range from polymorphic to monomorphic proliferated abnormal lymphocytes according to the World Health Organization (WHO) classification; the condition often develops following MTX administration for autoimmune diseases such as RA. ciated LPD are limited, its clinical features, standard treatment, and prognosis remain unclear. One currently established treatment for LPD is rituximab, which is a chimeric human/mouse anti-CD20 monoclonal antibody that effectively treats patients with CD20 + B-cell lymphoma and RA. [16] [17] [18] [19] [20] [21] In this study, we report the clinical characteristics and treatment outcomes for 9 patients with immunodeficiency-associated LPD observed at our institution over a 5-year period.
PATIENTS AND METHODS
Immunodeficiency-associated LPD was diagnosed in 9 of 245 patients (3.7%) with ML who were admitted to Miyazaki Prefectural Miyazaki Hospital between January 1, 2006, and December 20, 2010. These patients included 2 men and 7 women aged between 45 and 87 years (median age: 62 years). We retrospectively studied the incidence, etiology, clinical manifestations, diagnosis, treatment, and prognosis of immunodeficiency-associated LPD in these patients. The diagnosis of immunodeficiency-associated LPD was based on a combination of clinical characteristics, radiological findings, and histological features of the tumors. Case 5 has been reported on in detail as a case report. 22 Pathological studies were performed via H&E staining and immunohistochemical analysis of formalin-fixed, paraffin-embedded tissue sections.
According to the WHO classification and a previous report, 15 histological findings were categorized into four types: (i) diffuse large B-cell lymphoma (DLBCL), (ii) mucosa-associated lymphoid tissue (MALT) lymphoma, (iii) polymorphic B-cell LPD, and (iv) Hodgkin lymphoma-like LPD. The histological features of each type were as follows: (i) DLBCL: Atypical large CD20-positive B cells were observed. Lymphoma cells were positive for Epstein-Barr virus-encoded small RNAs (EBER) in EBER-positive cases.
(ii) MALT lymphoma: Atypical lymphoid cells had small to medium-sized irregular hyperchromatic nuclei with lymphoepithelial lesions and atypical cells were positive for CD20. Regarding the treatment strategy for immunodeficiencyassociated LPD patients, immediate MTX withdrawal was indicated when a clinical diagnosis of the condition was made. After MTX withdrawal, each patient was followed up with periodic physical examinations, including peripheral blood tests, and by radiological methods (chest radiography or abdominal ultrasound). When exacerbation of immunodeficiency-associated LPD was observed during the follow-up period after MTX withdrawal, administration of systemic chemotherapy was considered according to each patient's histological findings.
Approximately 4 weeks after MTX withdrawal without progression of immunodeficiency-associated LPD, final evaluation of treatment response was conducted using treatment response criteria. In consideration of each patient's performance status (PS), RA stage, organ dysfunction, treatment response, residual tumor, histological findings, and personal preferences, subsequent treatment was chosen from the following: rituximab, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), ABVD (doxorubicin [ The International Working Group 1999 response criteria recommended for non-Hodgkin lymphoma (NHL) were utilized to evaluate the treatment response of immunodeficiencyassociated LPD. 23 Complete response (CR) was defined as the disappearance of all clinical, microscopic, and radiographic evidence of disease. Partial response (PR) was defined as a 50% reduction in the sum of the products of the greatest diameters of measurable disease without the appearance of new lesions. 23 Stable disease (SD) was defined as failure to attain CR/PR or progressive disease. 23 Progressive disease or relapsed disease in other lesions was defined as a 50% increase from the nadir in the sum of the products of measurable disease or the appearance of new lesions. 23 The definitions of CR, PR, and SD required each criterion to be observed for a period of at least 4 weeks. 23 We did not perform a statistical analysis owing to the small number of cases involved. This retrospective study was conducted in compliance with good clinical practice and the ethical principles of the Declaration of Helsinki. Prior approval was obtained from the ethics review board at our institution.
RESULTS

The clinical characteristics of RA at immunodeficiencyassociated LPD diagnosis
Patients' clinical observations, physiological findings, radiological findings, and treatment were studied. The baseline characteristics of all patients are summarized in Tables 1 & 2. The patients included 2 men and 7 women aged between 45 and 87 years (median age: 62 years). The median history of RA was 5 years (range: 1-30 years). At initial diagnosis, 6 patients were diagnosed with advanced-stage RA, 3 of whom underwent total knee arthroplasty. However, 3 of 9 patients had early-stage RA. Thus, patients with immunodeficiencyassociated LPD had a tendency to possess poor prognostic factors of RA, such as the destruction of joints, positive findings of anti-cyclic citrullinated peptide antibody (anti-CCP antibody), high levels of rheumatoid factor, and high activity of RA. Surprisingly, immunodeficiency-associated LPD developed at both early and advanced stages of RA. Initial treatment for RA was patient-specific and included MTX, low-dose PSL, cyclosporine, mizoribine, and biologics in 9, 9, 1, 2, and 4 of the 9 patients, respectively. The median MTX dose was 8 ± 4 mg (range: 4-18 mg) per day, and the median duration of MTX treatment was 48 ± 29 months (range: 3-84 months). Four patients were treated with biologics consisting of infliximab, etanercept, or tocilizumab in 2, 1, and 1 patient, respectively. The complications observed at diagnosis included aortic regurgitation, paraplegia, non-tuberculous mycobacteria, and diabetes mellitus. One patient (case 4) exhibited paraplegia due to the depression of spine lesions.
The clinical characteristics and treatment outcomes of immunodeficiency-associated LPD
Similarly, patients' clinical observations, physiological findings, pathological findings, and treatment outcomes were studied for immunodeficiency-associated LPD. The baseline characteristics of all patients are summarized in Tables 1 & 2 . Initial symptoms at the development of immunodeficiencyassociated LPD are presented in Fig. 1 . Half of the patients experienced general fatigue, arthralgia, lymphadenopathy, and fever ( Fig. 1) . Most of these symptoms were not unique to immunodeficiency-associated LPD. In 6 of 9 patients, laboratory findings of serum lactate dehydrogenase values were slightly elevated (Tables 2 & 3) . Moreover, in 8 of 9 patients, laboratory values of serum soluble interlen-2 receptor were also slightly elevated (Tables 2 & 3) .
The histological findings of immunodeficiency-associated LPD are summarized for each case in Fig. 2 . There were 5 cases of DLBCL, 3 LPD cases, and 1 MALT lymphoma case. Of the 3 LPD cases, there was 1 HL-like LPD case, 1 case of LPD with histological findings, and 1 with clinical diagnosis. Extranodal ML was observed in the liver, spleen, stomach, oral area, salivary gland, spine, lungs, and skin in at least 1 of the 9 patients enrolled. Thus, more than half of the immunodeficiency-associated LPD patients (5/9) had DLBCL and extranodal lesions were observed in most. However, EpsteinBarr virus (EBV) positivity was detected in only 1 case of immunodeficiency-associated LPD. Most patients had advanced-stage disease (8/9, 88.8%) and were classified as being at high risk according to the international prognosis scoring system (7/9, 77.7%) at the time of immunodeficiencyassociated LPD development. Fig. 1 . Initial symptoms at the development of immunodeficiency-associated lymphoproliferative disorders. Half of the patients experienced general fatigue, arthralgia, lymphadenopathy, and fever. These symptoms were not unique to immunodeficiency-associated lymphoproliferative disorders.
The treatment outcomes for all 9 patients with immunodeficiency-associated LPD are shown in Fig. 3 . Following the development of immunodeficiency-associated LPD, MTX treatment was immediately discontinued in all patients. Approximately 4 weeks later, discontinuation of MTX led to CR, PR, and SD in 5, 1, and 3 patients, respectively. Thus, the response rate was 67% (6 of 9 patients). Relapse was observed in 3 of 5 CR patients in the MTX withdrawal remission group. Cases 1, 2, and 7 relapsed at 1, 10, and 12 months after CR, respectively. Since discontinuation of MTX was not sufficient for maintaining CR, subsequent treatment was provided on the basis of each patient's age, PS, RA stage, degree of treatment response, histological findings, residual tumor, and personal preferences. Conventional chemotherapy, rituximab alone, and radiation were administered to 4, 3, and 1 patient, respectively. For chemotherapy, polymorphic B-cell LPD patients received rituximab, whereas those with DLBCL received rituximab or R-CHOP, and HL-like LPD patients had ABVD.
Specifically, in CR (case 5) and SD patients with smaller tumor and fewer local lesions (cases 4 and 6), less intensive treatments than those commonly indicated for NHL were administered, including rituximab or radiation therapy. Eight courses of rituximab were administered in cases 5 and 6. Radiation therapy at 30 Gy was administered for the spine lesions in case 4 because of local lesions of immunodeficiency-associated LPD and poor PS. One patient (case 3) maintained CR without additional treatments.
Furthermore, in patients with large tumors (1 PR patient [case 9] and 1 SD patient [case 8]), the standard treatment for NHL with rituximab plus CHOP therapy was used. The regimen was administered for 2 courses in case 8 and 6 in case 9. In case 2, 4 additional courses of rituximab treatment were administered in lieu of 4 courses of rituximab plus CHOP therapy due to the onset of complications involving ileus and pulmonary abscess observed during treatments.
After relapse occurred in 3 of 4 patients in the MTXwithdrawal remission group, subsequent ABVD therapy (8 courses), rituximab (8 courses), or rituximab plus CHOP therapy (6 courses) was administered, leading to a second CR in cases 1, 2, and 7, respectively.
Thus, these treatments resulted in the attainment of CR in all 9 patients. The mean duration from diagnosis to CR was 91 days (range: 26-210 days). All patients maintained their disease-free status during the 23-month median follow-up period. Complications observed during treatments included lymphorrhea (case 1), antiphospholipid syndrome (APS; case 7), acute myocardial infarction (case 7), ileus (case 8), and pulmonary abscess (case 8). In case 7, acute myocardial infarction (AMI) developed during the treatment. Subsequent analysis showed that case 9 also manifested APS. In the LPD patient group receiving conventional chemotherapy such as rituximab plus CHOP, severe complications including antiphospholipid syndrome, AMI, ileus, and pulmonary abscess tended to occur during chemotherapy. In contrast, patients treated with less intensive treatment such as rituximab did not develop these severe complications.
RA control diminished during MTX discontinuation. However, in patients receiving regimens containing rituximab, the clinical symptoms and activity of RA were transiently well controlled. Therefore, subsequent RA treatments were provided, including low-dose PSL, tacrolimus, salazopyrin, and bucillamine in 8, 3, 4, and 2 cases, respectively. Surprisingly, 1 patient who received rituximab plus CHOP therapy showed long-lasting control of RA without further therapy.
DISCUSSION
Immunodeficiency-associated LPD with RA is reportedly most prevalent in elderly female patients with a longstanding history of RA, advanced-stage LPD, and B-cell phenotypes such as diffuse large B-cell lymphoma. [11] [12] [13] [14] However, the clinical features, standard treatment, and prognosis of patients with immunodeficiency-associated LPD remain unclear ow- ing to limited available reports (Table 4) . [11] [12] [13] [14] A recent report suggested that the risk factors predicting clinical outcomes in patients with immunodeficiency-associated LPD might be associated with older age (> 70 years), histology, EBV positivity, and monoclonality of immunoglobulin heavy chain gene. 15 Thus, immunodeficiency-associated LPD patients may exhibit a different clinical course and treatment outcome than that commonly observed in NHL patients with respect to regression following MTX discontinuation, extranodal lesions, advanced stage, RA-related complications before treatment, manifestation of complications during treatment, and especially the relatively good prognosis. Consequently, the clinical management of immunodeficiency-associated LPD patients may require a therapeutic strategy that differs from that often applied for NHL patients.
In the present retrospective study, we described the current clinical characteristics and treatment outcomes of immunodeficiency-associated LPD, including: (1) the development of immunodeficiency-associated LPD in both early and advanced stages of RA with various complications; (2) advanced-stage disease (8/9, 88. 8%) with high risk in the international prognosis scoring system at diagnosis in immunodeficiency-associated LPD; (3) a higher self-remission rate (66%) at diagnosis yet better response rate at relapse (100%) despite histological findings of EBV negativity and advanced stage in patients with immunodeficiency-associated LPD; (4) good prognosis from less intensive treatments, including MTX discontinuation and subsequent rituximab or rituximabcontaining treatment based on RA disease stage, performance status, and the extent of treatment response despite the limited number of patients enrolled; and (5) the need for careful treatment management owing to the tendency to develop severe complications during rituximab plus CHOP therapy. Thus, we herein described four clinically important points in the treatment and treatment management for immunodeficiency-associated LPD patients that may result in good outcomes.
First, immediate MTX withdrawal might be essential in the management of immunodeficiency-associated LPD. However, without other treatments, such withdrawal might only be transiently effective and the disease would eventually relapse. In previous reports, 7-13 the regression rate of immunodeficiency-associated LPD was approximately 30-40%, with a higher tendency observed in EBV-positive than in EBV-negative patients. In our study, the regression rate of all patients was 66%, whereas that of EBV-negative patients was 75% and the overall relapse rate was 75%. Surprisingly, Fig. 3 . Treatment outcomes of 9 patients with immunodeficiencyassociated lymphoproliferative disorders (LPD). After the development of immunodeficiency-associated LPD, discontinuation of methotrexate (MTX) resulted in complete remission (CR), partial remission (PR), and stable disease (SD) in 4, 2, and 3 patients, respectively. Relapse was observed in 3 of 4 CR patients in the MTX-withdrawal remission group. Subsequently, conventional chemotherapy, rituximab alone, and radiation were administered to 4, 3, and 1 patient, respectively. These treatments induced a second CR. Consequently, all patients remained disease-free during the median 23-month follow-up period. CHOP, doxorubicin, vincristine, cyclophosphamide, and prednisolone; ABVd, doxorubicin, bleomycin, vinblastine, dacarbazine during the 4-week period of MTX withdrawal, we did not observe exacerbation of immunodeficiency-associated LPD. Thus, our major concern was the subsequent therapeutic strategy for immunodeficiency-associated LPD following MTX discontinuation.
Second, less intensive treatments than those commonly indicated for NHL successfully provided good outcomes for patients in our study. Most of them had advanced-stage diseases (8/9, 88. 8%) and were classified as at high risk or high/intermediate risk according to the international prognosis scoring system (7/9, 77.7%) at the time of immunodeficiencyassociated LPD development. In a previous report describing NHL patients without RA, 25 the 5-year survival rates of those at high risk and high/intermediate risk were reported to be 46% and 32%, respectively. In our retrospective study, although the observation period was relatively short (median: 23 months), all 9 immunodeficiency-associated LPD patients showed good response and good survival. These RA patients already had several complications and decreased PS prior to immunodeficiency-associated LPD treatment; thus, the less intensive treatments provided might be efficient therapeutic modalities in this patient population when properly adjusted on a case-by-case basis.
Third, LPD (polymorphic B-cell LPD and clinical diagnosis) was the second most prevalent histological finding (3/9 cases), although DLBCL was the most common (5/9 cases). These LPD patients were speculated to belong to the oligoclonal-polyclonal group in the multi-step oncogenesis mechanism of LPD. According to a previous report, 15 rituximab is effective in some polymorphic B-cell LPD patients, which was also the case in our study. Such effectiveness might be due to the atypical cells in polymorphic B-cell LPD occasionally being positive for CD20. On the basis of the response to MTX discontinuation and patient background, it may be appropriate to treat those with lower residual tumors that respond to MTX discontinuation with rituximab. According to previous reports on the safety, effectiveness, and feasibility of rituximab for the treatment of newly diagnosed low-grade lymphoma with low tumor burden, relapsed or refractory low-grade lymphoma, and DLBCL, [26] [27] [28] [29] the agent was recently approved for immunodeficiency-associated LPD via the procedure of public knowledge-based application by the Japanese Ministry of Health, Labour and Welfare. In the future, rituximab therapy may become a mainstay therapeutic strategy for immunodeficiency-associated LPD.
Finally, severe and potentially lethal complications such as AMI, pulmonary abscess, and ileus were promptly diagnosed and well managed by our team of excellent cardiologists and surgeons. Two of the 3 immunodeficiency-associated LPD patients receiving rituximab plus CHOP therapy developed severe complications such as ileus and pulmonary abscess (case 8), AMI, and APS (case 7). In the group with large residual tumor that does not respond to MTX discontinuation, it may be appropriate to treat with rituximab combined Table 4 . Previous reports of immunodeficiency-associated lymphoproliferative disorders (LPD) and present cases at our institution
